Cardiovascular and Bleeding Risks Associated With Nonsteroidal Anti-Inflammatory Drugs After Myocardial Infarction
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kang, Dong Oh | - |
dc.contributor.author | An, Hyong gin | - |
dc.contributor.author | Park, Geun U | - |
dc.contributor.author | Yum, Yunjin | - |
dc.contributor.author | Park, Eun Jin | - |
dc.contributor.author | Park, Yoonjee | - |
dc.contributor.author | Jang, Won Young | - |
dc.contributor.author | Kim, Woo Hyeun | - |
dc.contributor.author | Choi, Jah Yeon | - |
dc.contributor.author | Roh, Seung Young | - |
dc.contributor.author | Na, Jin Oh | - |
dc.contributor.author | Kim, Jin Won | - |
dc.contributor.author | Kim, Eung Ju | - |
dc.contributor.author | Rha, Seung Woon | - |
dc.contributor.author | Park, Chang Gyu | - |
dc.contributor.author | Seo, Hong Seog | - |
dc.contributor.author | Choi, Cheol Ung | - |
dc.date.available | 2020-10-30T06:53:45Z | - |
dc.date.issued | 2020-08 | - |
dc.identifier.issn | 0735-1097 | - |
dc.identifier.issn | 1558-3597 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/822 | - |
dc.description.abstract | BACKGROUND Limited data are available regarding the risk for adverse clinical events with concomitant nonsteroidal anti-inflammatory drug (NSAID) treatment after myocardial infarction (MI). OBJECTIVES The aim of this study was to investigate the risk for cardiovascular and bleeding events according to groups of antithrombotic medications and subtypes of NSAIDs in patients with MI. METHODS This was a nationwide cohort study to enroll a study population from the Health Insurance Review and Assessment Service database in Korea between 2009 and 2013. Patients were divided into groups on the basis of the prescribed antithrombotic medications. The primary and secondary outcomes were thromboembolic cardiovascular and clinically relevant bleeding events. The risk for adverse clinical events was assessed by ongoing NSAID treatment and subtypes of NSAIDs. RESULTS In total, 108,232 patients (mean age 64.2 +/- 12.8 years, 72.1% men, mean follow-up duration 2.3 +/- 1.8 years) with first diagnosed MI were enrolled. Concomitant NSAID treatment significantly increased the risk for cardiovascular events (hazard ratio [HR]: 6.96; 95% confidence interval [CI]: 6.24 to 6.77; p < 0.001) and bleeding events (HR: 4.08; 95% CI: 3.51 to 4.73; p < 0.001) compared with no NSAID treatment. Among NSAID subtypes, the risk for cardiovascular and bleeding events was lowest with the use of celecoxib (HR: 4.65; 95% CI: 3.17 to 6.82; p < 0.001, and 3.44; 95% CI: 2.20 to 5.39; p < 0.001, respectively) and meloxicam (HR: 3.03; 95% CI: 1.68 to 5.47; p < 0.001, and 2.80; 95% CI: 1.40 to 5.60; p < 0.001, respectively). CONCLUSIONS Concomitant NSAID treatment significantly increased the risk for cardiovascular and bleeding events after MI. Although NSAID treatment should be avoided after MI, celecoxib and meloxicam could be considered as alternative options in cases in which NSAID use is unavoidable. (c) 2020 by the American College of Cardiology Foundation. | - |
dc.format.extent | 12 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Elsevier BV | - |
dc.title | Cardiovascular and Bleeding Risks Associated With Nonsteroidal Anti-Inflammatory Drugs After Myocardial Infarction | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1016/j.jacc.2020.06.017 | - |
dc.identifier.scopusid | 2-s2.0-85088142968 | - |
dc.identifier.wosid | 000553777900005 | - |
dc.identifier.bibliographicCitation | Journal of the American College of Cardiology, v.76, no.5, pp 518 - 529 | - |
dc.citation.title | Journal of the American College of Cardiology | - |
dc.citation.volume | 76 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 518 | - |
dc.citation.endPage | 529 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.subject.keywordPlus | EXPERT CONSENSUS STATEMENT | - |
dc.subject.keywordPlus | DUAL ANTIPLATELET THERAPY | - |
dc.subject.keywordPlus | EAST-ASIAN PATIENTS | - |
dc.subject.keywordPlus | EUROPEAN-SOCIETY | - |
dc.subject.keywordPlus | FOCUSED UPDATE | - |
dc.subject.keywordPlus | 2017 ESC | - |
dc.subject.keywordPlus | CYCLOOXYGENASE | - |
dc.subject.keywordPlus | INHIBITORS | - |
dc.subject.keywordPlus | CYCLO-OXYGENASE-2 | - |
dc.subject.keywordPlus | METAANALYSIS | - |
dc.subject.keywordAuthor | antithrombotic therapy | - |
dc.subject.keywordAuthor | celecoxib | - |
dc.subject.keywordAuthor | meloxicam | - |
dc.subject.keywordAuthor | myocardial infarction | - |
dc.subject.keywordAuthor | nonsteroidal anti-inflammatory drugs | - |
dc.subject.keywordAuthor | safety | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.